Invesco
MRNS

Invesco’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Invesco’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,708
Closed -$214K – 4018
2024
Q1 		$214K Buy
23,708
+554
+2% +$5.38K ﹤0.01% 3621
2023
Q4 		$252K Sell
23,154
-20,788
-47% -$156K ﹤0.01% 3485
2023
Q3 		$354K Sell
43,942
-385,063
-90% -$3.2M ﹤0.01% 3366
2023
Q2 		$4.66M Buy
+429,005
New +$3.67M ﹤0.01% 2283
2022
Q2 		– Sell
-13,754
Closed -$129K – 4178
2022
Q1 		$129K Buy
13,754
+391
+3% +$3.88K ﹤0.01% 3840
2021
Q4 		$158K Sell
13,363
-1,281
-9% -$14.8K ﹤0.01% 3831
2021
Q3 		$166K Buy
14,644
+2,889
+25% +$39.7K ﹤0.01% 3853
2021
Q2 		$210K Buy
+11,755
New +$189K ﹤0.01% 3771
2019
Q1 		– Sell
-3,014
Closed -$35K – 3855
2018
Q4 		$35K Sell
3,014
-1,376
-31% -$27.8K ﹤0.01% 3727
2018
Q3 		$176K Sell
4,390
-256
-6% -$7.29K ﹤0.01% 3721
2018
Q2 		$131K Buy
4,646
+1,387
+43% +$30.7K ﹤0.01% 3755
2018
Q1 		$50K Buy
+3,259
New +$77.6K ﹤0.01% 3685

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco's MRNS Position: Q2 2024 in Review

Invesco sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 23,708 shares — an estimated $214K sold.

Invesco first reported a position in MRNS in Q1 2018 and held it in 12 quarters. The position peaked at $4.66M in Q2 2023. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

  • Invesco reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
  • Invesco sold 23,708 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $214K.
  • Invesco first reported a position in Marinus Pharmaceuticals, Inc in Q1 2018 and held it in 12 quarters.
  • Invesco's Marinus Pharmaceuticals, Inc position peaked at $4.66M in Q2 2023.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Invesco's 13F filing for Q2 2024, filed 13 Aug 2024.